NCT06084052 Path Active Multicentre Randomised Controlled Trial (Previous Pilot: Path Active; Safety and Tolerability Study)
| NCT ID | NCT06084052 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Royal Free Hospital NHS Foundation Trust |
| Condition | Diabetic Foot |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-04-02 |
| Primary Completion | 2025-12-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Path Active™ comprises a pair of monitoring insoles which measure parameters associated with foot ulceration in diabetes: temperature and pressure. The insoles are linked via an app to the wearer's mobile phone and also to a clinical dashboard so that both wearer and clinician are alerted to early signs of skin damage on the foot so that immediate preventive action can be taken. The study is a multisite randomised controlled trial which will evaluate the effectiveness of Path Active™ in 60 people with diabetes who are at 'high risk' of foot ulceration, compared with 60 people who receive their usual podiatry foot checks over a period of 12 weeks.
Eligibility Criteria
Inclusion Criteria: * • Participant able to give informed consent. * Age \>18 at the time of consent. * Diagnosis of Type 1 or Type 2 Diabetes. * Both Feet Intact (no ulceration). * Participant understands and is willing to participate and can comply with the follow-up regime. * Participant diabetes foot Risk Stratification as 'High Risk' as in Frame (2021) Scotland/England https://www.diabetesframe.org/ * Ability to walk independently for \> 100 metres i.e without use of wheelchair, walking stick or personal assistance. * Participant able and willing to wear suitable footwear. * Must own a mobile phone and be willing to upload WWP app. Exclusion Criteria: * Either foot has less than 2 arterial vessel run-off on Doppler. * Poor visual acuity ie registered blind, unless supported by carer. * Current participation in another clinical investigation of a medical device or a drug; or participation in such a study within 30 days prior to study enrolment. * Body Mass Index (BMI) \>40. * Parti